Statistics from Altmetric.com
Ault KA, for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–8.
Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Gynaecology ★★★★★★⋆ Public health ★★★★★★⋆
prespecified combined analysis of 4 randomised controlled trials.
blinded (clinicians, participants, outcome assessors, and adjudication committee).*
mean 3 years (maximum 4 y). Follow-up started on day 1 in the intention-to-treat and susceptible populations and 1 month after the third dose of vaccine in the per protocol population.
clinics in North America, Latin America, …
Source of funding: Merck Research Laboratories.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.